Based on the above results, we determined that targeting HPD with small molecule inhibitors blocks its binding to mRNA and inhibits the development of ovarian cancer, as well as enhances the Taxol response, which provides a new theoretical basis for clinical medication. The gene discussed is HPD; the disease is ovarian cancer.